Alnylam Pharmaceuticals reported strong Q2 2024 financial results with total revenues of $659.8 million, up 107% year-over-year. Net product revenues grew 34% to $410.1 million, driven by AMVUTTRA sales of $230.1 million. Net revenues from collaborations surged to $227.3 million, while royalty revenue increased to $22.4 million.The company maintained solid operational performance with R&D expenses of $294.1 million and SG&A expenses of $248.4 million. Operating income was $48.6 million compared to a loss of $229.8 million in Q2 2023. Net loss narrowed significantly to $16.9 million from $276.0 million last year, reflecting improved operational efficiency and strong commercial execution.Looking ahead, Alnylam expects continued growth from its commercial portfolio and advancing pipeline. The company ended the quarter with $2.62 billion in cash and investments. Management remains focused on achieving financial self-sustainability by the end of 2025 through sustainable innovation and exceptional financial performance while delivering transformative medicines globally.

Alnylam Pharmaceuticals reported strong Q2 2024 financial results with total revenues of $659.8 million, up 107% year-over-year. Net product revenues grew 34% to $410.1 million, driven by AMVUTTRA sales of $230.1 million. Net revenues from collaborations surged to $227.3 million, while royalty revenue increased to $22.4 million.The company maintained solid operational performance with R&D expenses of $294.1 million and SG&A expenses of $248.4 million. Operating income was $48.6 million compared to a loss of $229.8 million in Q2 2023. Net loss narrowed significantly to $16.9 million from $276.0 million last year, reflecting improved operational efficiency and strong commercial execution.Looking ahead, Alnylam expects continued growth from its commercial portfolio and advancing pipeline. The company ended the quarter with $2.62 billion in cash and investments. Management remains focused on achieving financial self-sustainability by the end of 2025 through sustainable innovation and exceptional financial performance while delivering transformative medicines globally.